Drugs / anti-EGFR-IL-dox
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02833766 | Oct 2016 → Oct 2020 | breast cancer | Swiss Cancer Institute | Terminated | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-EGFR-IL-dox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02833766 ↗ |
| Known as | anti-EGFR-ILs-dox | “We have developed an anti-EGFR targeted nanocontainer drug by inserting anti-EGFR antibody fragments into the membrane of pegylated liposomes (anti-EGFR-ILs-dox).” PMID 36879012 ↗ Mar 2023 |
| Modality | Other / unclassified | “anti-EGFR targeted nanocontainer drug” PMID 36879012 ↗ Mar 2023 |
| Route | Intravenous | “given at a dose of 50 mg/m2 intravenous” NCT02833766 ↗ |
| Target | EGFR | “We have developed an anti-EGFR targeted nanocontainer drug by inserting anti-EGFR antibody fragments into the membrane of pegylated liposomes (anti-EGFR-ILs-dox).” PMID 36879012 ↗ Mar 2023 |